Engineering the future of medicine: Natural products, synthetic biology and artificial intelligence for next-generation therapeutics.

Journal: Clinical and translational medicine
PMID: 39856487

Abstract

The eXchange Unit between Thiolation domains approach and artificial intelligence (AI)-driven tools like Synthetic Intelligence are transforming nonribosomal peptide synthetase and polyketide synthase engineering, enabling the creation of novel bioactive compounds that address critical challenges like antibiotic resistance and cancer. These innovations expand chemical space and optimize biosynthetic pathways, offering precise and scalable therapeutic solutions. Collaboration across synthetic biology, AI, and clinical research is essential to translating these breakthroughs into next-generation treatments and revolutionizing drug discovery and patient care.

Authors

  • Emre F Bülbül
    Synthetic Biology of Microbial Natural Products, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), PharmaScienceHub (PSH), Saarbrücken, Germany.
  • Helge B Bode
    Department of Natural Products in Organismic Interactions, Max Planck Institute for Terrestrial Microbiology, Marburg, Germany.
  • Steven Schmitt
    Myria Biosciences AG, Tech Park Basel, Basel, Switzerland.
  • Kenan A J Bozhüyük
    Synthetic Biology of Microbial Natural Products, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), PharmaScienceHub (PSH), Saarbrücken, Germany.

Keywords

External Resources

Popular Topics
Recent Journals